改进技术植入生物可吸收冠脉支架的5年结局
ABSORB IV随机双盲试验纳入2604例稳定或急性冠脉综合征患者,比较改进技术植入的依维莫司洗脱生物可吸收支架(BVS)与钴铬依维莫司洗脱支架(CoCr-EES)。5年靶病变失败率BVS组17.5%、CoCr-EES组14.5%(P=0.03),差异主要见于3年内,3至5年事件率相似;心绞痛复发率两组相当。
要点
- 改进技术植入BVS的5年靶病变失败率仍比CoCr-EES高约3%。
- BVS事件风险增加仅限前3年,即支架完全生物吸收时间点。
- 5年内心绞痛复发频繁,但BVS与CoCr-EES两组相当。
核心结论
- 尽管采用改进植入技术,BVS的5年靶病变失败绝对发生率仍比CoCr-EES高3%。
- BVS事件风险增加的时间窗限于3年内,此后事件率与CoCr-EES相似。
- 5年随访期间心绞痛复发常见,但两种器械间无差异。
研究设计与样本
- ABSORB IV为大规模、双盲随机对照试验,147个中心共随机2604例稳定或急性冠脉综合征患者。
- 患者、临床评估者及事件裁定者对随机分组设盲,随访至5年。
主要发现
- 5年靶病变失败:BVS组216例(17.5%),CoCr-EES组180例(14.5%),P=0.03。
- 5年内器械血栓:BVS组21例(1.7%),CoCr-EES组13例(1.1%),P=0.15。
- BVS事件率在3年随访内略高于CoCr-EES,3至5年间两组相似。
- 5年内经中心裁定的心绞痛复发:BVS组659例(累积率53.0%),CoCr-EES组674例(53.3%),P=0.63。
临床怎么用
- 选择BVS时应告知患者5年靶病变失败率略高于CoCr-EES,但额外风险主要集中在术后3年内。
- BVS与CoCr-EES术后5年心绞痛复发率均较高且相当,需关注长期症状管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bioresorbable vascular scaffolds (BVS) were designed to improve late event-free survival compared with metallic drug-eluting stents. However, initial trials demonstrated worse early outcomes with BVS, in part due to suboptimal technique. In the large-scale, blinded ABSORB IV trial, polymeric everolimus-eluting BVS implanted with improved technique demonstrated noninferior 1-year outcomes compared with cobalt chromium everolimus-eluting stents (CoCr-EES). OBJECTIVES: This study sought to evaluate the long-term outcomes from the ABSORB IV trial. METHODS: We randomized 2,604 patients at 147 sites with stable or acute coronary syndromes to BVS with improved technique vs CoCr-EES. Patients, clinical assessors, and event adjudicators were blinded to randomization. Five-year follow-up was completed. RESULTS: Target lesion failure at 5 years occurred in 216 (17.5%) patients assigned to BVS and 180 (14.5%) patients assigned to CoCr-EES (P = 0.03). Device thrombosis within 5 years occurred in 21 (1.7%) BVS and 13 (1.1%) CoCr-EES patients (P = 0.15). Event rates were slightly greater with BVS than CoCr-EES through 3-year follow-up and were similar between 3 and 5 years. Angina, also centrally adjudicated, recurred within 5 years in 659 patients (cumulative rate 53.0%) assigned to BVS and 674 (53.3%) patients assigned to CoCr-EES (P = 0.63). CONCLUSIONS: In this large-scale, blinded randomized trial, despite the improved implantation technique, the absolute 5-year rate of target lesion failure was 3% greater after BVS compared with CoCr-EES. The risk period for increased events was limited to 3 years, the time point of complete scaffold bioresorption; event rates were similar thereafter. Angina recurrence after intervention was frequent during 5-year follow-up but was comparable with both devices.(Absorb IV Randomized Controlled Trial; NCT02173379).
引用
- Stone GW, Kereiakes DJ, Gori T, et al. 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique. J Am Coll Cardiol. 2023. PMID: 37207924. doi:10.1016/j.jacc.2023.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。